Press Room

Press Room

  • Jul 1st, 2018
    InsightSuccess featuring NLS’ CEO

    VIEW INTERVIEW

  • Aug 22, 2018
    NLS-1 Pharma’s CEO Alex Zwyer interview at Business Worldwide Magazine

    VIEW INTERVIEW

  • Jul 20, 2018
    NLS-1 Pharma’s CEO Alex Zwyer interviewed at The London Stock Exchange Studios

    WATCH FULL INTERVIEW

  • May, 2018
    New Era in the ADHD Space

    READ THE NEWS

  • Mar, 2018
    A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)

    READ THE NEWS

  • June, 2017
    NLS-1 touts Mazindol's efficacy as it takes on ADHD market

    READ THE NEWS

  • June, 2017
    NLS-1 phase II results advance effort to carve out alternative ADHD drug niche

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS-1 Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS-1 Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS

  • June, 2017
    Another old, cheap generic is being prepped for an FDA application — made over into a ‘new’ drug for ADHD and narcolepsy

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS-1 touts positive ADHD data, plots late-stage tests

    READ THE NEWS

  • June, 2017
    Potential Treatment for ADHD Yields Positive Phase II Data

    READ THE NEWS

  • June, 2017
    NLS-1 Pharma’s new ADHD compound could break the focus of the field

    READ THE NEWS

  • June, 2017
    The Handoff: Your Week in Neurology News

    READ THE NEWS

  • June, 2017
    Is ADHD a sleep disorder? Stimulant drug improves symptoms

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS-1 Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS

  • June, 2017
    NLS-1 Pharma Pins Hopes On Ex-Obesity Drug For ADHD

    READ THE NEWS

  • June, 2017
    Mid-stage data show promise for mazindol C-R

    READ THE NEWS

  • June, 2017
    NLS-1 Pharma’s results offer hope of changing ADHD landscape

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS-1 Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS